Stock Analiz

Oramed Pharmaceuticals Inc. ORMP

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$3.71Market cap $161M
Open the interactive analysis →

Oramed Pharmaceuticals Inc. (ORMP) is a healthcare company listed in the US with a market value of about $161M.

Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is value (3/5); the weakest is future growth (0/5).

Key numbers: a P/E of 0.9, a 5-year average ROIC of -11%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 97% below the current price.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $641000 in 2016 to $3M in 2022, growth of about 27.1% a year. It was profitable in 2 of the last 10 years in our data. Its share count rose by 9% over three years (dilution for shareholders).

Score: 1.6 / 5

Value3/5
Future growth0/5
Track record2/5
Financial health2/5
Shareholder returns1/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • PEG below 1.5
  • 5-year EPS growth above 10% a year
  • ROE above 15%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets
  • Pays a dividend

Checks not passed

  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year

Valuation

P/E (TTM)0.9
Forward P/E0.8
P/FCF—
P/S—
P/B0.5
EV/EBITDA—
PEG0.04
Dividend yield6.78%
FCF yield-2.0%
Shareholder yield9.7%
Intrinsic value vs. price−97%

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)21.8%
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-1101.6%
ROIC (5-yr avg.)-11.3%
Profitable years (of last 10)2
Years paying a dividend1

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue———$3M$3M$3M$3M$2M$2M$641000
Net income$64M-$19M$5M-$37M-$23M-$12M-$14M-$13M-$10M-$11M
Free cash flow-$9M-$8M-$11M-$28M-$22M-$13M-$13M-$15M-$6M$5M
EPS (diluted)$1.50$-0.48$0.14$-0.94$0.78$0.56$0.82$0.86$0.79$0.87
Net margin———-1352.6%-850.5%-424.8%-531.1%-519.7%-426.7%-1710.5%
ROIC-6.4%-6.9%-5.8%-21.0%-16.5%-28.2%-39.6%-25.1%-44.2%-30.2%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 1 analysts is $7.00, 89% above the current price; targets range from $7.00 to $7.00; the consensus rating is “none”; expected EPS is $4.47 for the fiscal year ending December 31, 2026.

Frequently asked questions

What is Oramed Pharmaceuticals’s P/E ratio?

About 0.9, based on the last twelve months of diluted earnings per share (forward P/E about 0.8).

Is Oramed Pharmaceuticals stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 97% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Oramed Pharmaceuticals pay a dividend?

Yes. The dividend yield is about 6.78%, and it has paid dividends for 1 years in our data.

Is Oramed Pharmaceuticals a good stock to buy?

We do not give buy or sell advice. Oramed Pharmaceuticals scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.